New combo attack on tough lymphoma: two immune therapies join forces
NCT ID NCT06213311
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two immune-based therapies—axicabtagene ciloleucel (a CAR T-cell therapy) and glofitamab (a bispecific antibody)—in 40 people with large B cell lymphoma that has relapsed or not responded to first treatment. The goal is to see if the combination can control the disease better than standard options. Participants will receive both drugs by IV, and the study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axicabtagene ciloleucel (a CAR T-cell therapy) and glofitamab (a bispecific antibody)
What this could lead to
If successful, this combination could offer a new second-line treatment option for people with large B cell lymphoma that has come back or not responded to initial therapy.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The combination may cause serious side effects, and it is not yet known if it works better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact